Byetta LAR Will Become Decision Resources' New Clinical Gold Standard in 2013 for the Treatment of Type 2 Diabetes

Wednesday, January 27, 2010 Diabetes News
Email Print This Page Comment bookmark
Font : A-A+

WALTHAM, Mass., Jan. 26 Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Amylin/Eli Lilly/Alkermes' Byetta LAR earns Decision Resources' proprietary clinical gold standard status in 2013 for the treatment of type 2 diabetes following its approval for the indication in 2010. Byetta LAR has competitive advantages over currently available and emerging drugs in efficacy and delivery.

"Byetta LAR improves on our current gold standard, Amylin/Eli Lilly's Byetta, by offering superior glucose-lowering and weight-loss efficacy with a more convenient dosing schedule (once-weekly versus twice-daily injections)," stated Decision Resources' Analyst Christine Helliwell, Ph.D. "According to surveyed endocrinologists, Byetta LAR is expected to gain the greatest patient share among emerging type 2 diabetes therapies. Byetta LAR will primarily take patient share away from Byetta; we expect metformin to continue being the patient share leader in the future."

The new report entitled Type 2 Diabetes: Despite the Domination of Entrenched, Generic, Oral Therapies, Blockbuster Potential Awaits a Once-Weekly GLP-1 Analogue also finds that a once-weekly glucagon-like peptide (GLP-1) analogue would earn 40 percent patient share in type 2 diabetes according to surveyed U.S. endocrinologists. In contrast, in Europe, such a drug would earn a substantially lower patient share of 20 percent, according to surveyed European endocrinologists.

"The lower patient share in Europe likely reflects the region's stricter reimbursement requirements and its generally more conservative uptake of novel drugs," added Dr. Helliwell.

About the Report

Type 2 Diabetes: Despite the Domination of Entrenched, Generic, Oral Therapies, Blockbuster Potential Awaits a Once-Weekly GLP-1 Analogue is a DecisionBase 2010 report. DecisionBase 2010 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development.

About Decision Resources

Decision Resources ( is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at

All company, brand or product names contained in this document may be trademarks or

registered trademarks of their respective holders.

For more information, contact: Decision Resources Decision Resources, Inc. Gisselle Morales Christopher Comfort 781-296-2691 781-296-2597

SOURCE Decision Resources

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store